304 related articles for article (PubMed ID: 21283552)
1. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Keller MJ; Madan RP; Torres NM; Fazzari MJ; Cho S; Kalyoussef S; Shust G; Mesquita PM; Louissaint N; Chen J; Cohen HW; Diament EC; Lee AC; Soto-Torres L; Hendrix CW; Herold BC
PLoS One; 2011 Jan; 6(1):e16475. PubMed ID: 21283552
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.
Herold BC; Dezzutti CS; Richardson BA; Marrazzo J; Mesquita PM; Carpenter C; Huber A; Louissaint N; Marzinke MA; Hillier SL; Hendrix CW
J Acquir Immune Defic Syndr; 2014 May; 66(1):65-73. PubMed ID: 24457633
[TBL] [Abstract][Full Text] [Related]
3. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators.
Dezzutti CS; Hendrix CW; Marrazzo JM; Pan Z; Wang L; Louissaint N; Kalyoussef S; Torres NM; Hladik F; Parikh U; Mellors J; Hillier SL; Herold BC
PLoS One; 2011; 6(8):e23136. PubMed ID: 21858008
[TBL] [Abstract][Full Text] [Related]
4. A perspective on progress and gaps in HIV prevention science.
Kiser PF; Mesquita PM; Herold BC
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871
[TBL] [Abstract][Full Text] [Related]
5. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
6. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
7. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
[TBL] [Abstract][Full Text] [Related]
8. Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.
Jacot TA; Nelson A; Thurman A; Kashuba AD; Archer DF; Doncel GF
PLoS One; 2014; 9(12):e114368. PubMed ID: 25489736
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
McGowan I; Hoesley C; Cranston RD; Andrew P; Janocko L; Dai JY; Carballo-Dieguez A; Ayudhya RK; Piper J; Hladik F; Mayer K
PLoS One; 2013; 8(4):e60147. PubMed ID: 23573238
[TBL] [Abstract][Full Text] [Related]
11. Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract.
Lahey T; Ghosh M; Fahey JV; Shen Z; Mukura LR; Song Y; Cu-Uvin S; Mayer KH; Wright PF; Kappes JC; Ochsenbauer C; Wira CR
PLoS One; 2012; 7(6):e38100. PubMed ID: 22675510
[TBL] [Abstract][Full Text] [Related]
12. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
[TBL] [Abstract][Full Text] [Related]
13. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
14. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
Delany-Moretlwe S; Lombard C; Baron D; Bekker LG; Nkala B; Ahmed K; Sebe M; Brumskine W; Nchabeleng M; Palanee-Philips T; Ntshangase J; Sibiya S; Smith E; Panchia R; Myer L; Schwartz JL; Marzinke M; Morris L; Brown ER; Doncel GF; Gray G; Rees H
Lancet Infect Dis; 2018 Nov; 18(11):1241-1250. PubMed ID: 30507409
[TBL] [Abstract][Full Text] [Related]
16. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
17. Vaginal deployment and tenofovir delivery by microbicide gels.
Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Assessment of Systemic and Genital Tract Inflammatory Markers and Endogenous Genital Tract E. coli Inhibitory Activity in HIV-Infected and Uninfected Women.
Keller MJ; McGinn AP; Lo Y; Huber A; Espinoza L; Minkoff H; Colie C; Nowicki MJ; D'Souza G; Anastos K
Am J Reprod Immunol; 2016 Jun; 75(6):631-42. PubMed ID: 27145926
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
Wilson SS; Cheshenko N; Fakioglu E; Mesquita PM; Keller MJ; Herold BC
Antivir Ther; 2009; 14(8):1113-24. PubMed ID: 20032541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
